November 7, 2016
Fitch Even partner Paul B. Henkelmann was quoted in an article published online in last week’s edition of Chemical & Engineering News, a publication of the American Chemical Society.
The article, titled "Hedge Fund Manager Wins U.S. Drug Patent Challenges," discusses recent Patent Trial and Appeal Board rulings that invalidated claims of a Shire PLC patent covering its drug Gattex and claims of two Celgene Corp. patents related to the cancer drugs Thalomid, Revlimid, and Pomalyst. The Coalition for Affordable Drugs, an organization started by hedge fund manager Kyle Bass, had challenged the validity of these patents, among others.
- Fitch Even Partner Tom Lebens to Copresent AIPLA Webinar on Trade SecretsJuly 6, 2020 Read more
IP Alert | USPTO Launches Fast-Track Appeals Pilot Program TodayJuly 2, 2020
The USPTO has announced that beginning today the PTAB will begin accepting petitions for expedited resolution of ex parte appeals under the newly launched Fast-Track Appeals Pilot Program. Read more